Clinical Trial Update: Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial [Phase 2]

View source ↗

Summary

An open-label Phase 2 trial evaluating continuation of serplulimab plus chemotherapy after first progression in advanced gastric or gastro-esophageal junction a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Serplulimab (serplulimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) | Phase 2 | Status: UNKNOWN